Etanercept and quality attributes changes

Biosimilars/Research | Posted 27/05/2011 post-comment0 Post your comment

Quality changes in commercially available etanercept (Enbrel) were found by Sandoz researchers over a period of time. Since the drug remained on the market with an unchanged label, this would indicate that the changes were accepted by the health authorities [1].


The research analysed multiple commercial batches of the glycosylated recombinant therapeutic protein etanercept (Enbrel) which were available on the EU and US markets.

Glycan mapping and caution exchange chromatography were used in order to study the glycans and different acid/basic variants present in the molecule.

Results showed highly consistent quality attributes for batches expiring before the end of 2009. From 2010 onwards batches with a different quality profile appeared in parallel to the original version.

Major differences were found in the glycosylation profile and in the amount of basic variants present in the molecule. Variants containing N-glycan G2F decreased from 50% to 30% and C-terminal lysine increased from 15% to 30%.

This seems to be good news for biosimilars – which are trying to prove ‘similarity’. Since, if the originators themselves can show such variation in quality attributes, then biosimilars may find it easier to prove ‘similarity’ than may have been thought.

Related articles

Quality attributes changes for rituximab

Changes in the quality attributes of darbepoetin alfa

Acceptable changes in quality for glycosylated biologicals


1. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-2.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010